Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage preclinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbo
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
3. Pharmacyclics, Inc. Rights Offering Oversubscribed
4. Pharmacyclics Announces Subscription Price for Rights Offering
5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
9. Pharmacyclics Secures $5.0 Million in Debt Financing
10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, ... today announced that it will host a webcast on June 8, ... 6th at the 14th Congress of the European Hematology Association. ... www.micromet-inc.com . , , Forum: ...
... VIEW, Calif., June 2 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and ... featured in two podium presentations during the 69th Scientific ... from June 5-9, 2009 in New Orleans, Louisiana. ...
... June 2 BioGenex, a developer of innovative instruments ... molecular diagnostics, announced today that Abbott has entered into ... distribution agreement to market the Xmatrx(R) platform for the ... terms of the agreement Abbott customers will have the ...
Cached Biology Technology:Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 3Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 4Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 2Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 3Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... study funded by the New Jersey Recovery Fund and ... of Planning and Public Policy at Rutgers University has ... skeptical about the likelihood of community-based rebuilding solutions. Of ... indicated they were "pessimistic" or "very pessimistic" that the ... be rebuilt better than they were before the storm; ...
(Date:7/24/2014)... life arose have been maintained in our cells today according ... published today in the Journal of Biological Chemistry ... in animals still perform ancient reactions thought to have been ... years ago. , The primordial soup theory suggests that life ... the combination of metals, gases from the atmosphere and some ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... reported preclinical study results, which demonstrate the ... cells (ADRCs) for the treatment of damaged ... tissue density and disc-specific extracellular matrix components ... animal model. The data were presented today ...
... Society (ACS) News Service Weekly PressPac with news from ACS, ... credit the individual journal or the American Chemical Society as ... IMMEDIATE RELEASE EXCEPT ARTICLE #5, which is embargoed for 9 ... PressPac Archive: ARTICLE ...
... and abnormalities in metabolism and diabetes has been suggested in ... Oxford, the Wellcome Trust Sanger Institute and the MRC Epidemiology ... involved in the way the body responds to the 24 ... sugar levels and an increased risk of type 2 diabetes. ...
Cached Biology News:Cytori reports benefit of adipose-derived regenerative cells in spinal disc model 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 2American Chemical Society's Weekly PressPac -- Dec. 3, 2008 3American Chemical Society's Weekly PressPac -- Dec. 3, 2008 4American Chemical Society's Weekly PressPac -- Dec. 3, 2008 5American Chemical Society's Weekly PressPac -- Dec. 3, 2008 6American Chemical Society's Weekly PressPac -- Dec. 3, 2008 7American Chemical Society's Weekly PressPac -- Dec. 3, 2008 8Discovery of new gene associated with diabetes risk suggests link with body clock 2
... DASGIP Overhead Drive for individual and ... for flexible agitation of DASGIP vessels, featuring ... impellers. ,Up to 16 overhead drives ... DASGIP Cultivation Systems fedbatch-pro® and cellferm-pro® for ...
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The system is especially dedicated ... standard system for Western blotting applications.,Fuiji's ...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... the space and time dimensions of a streak ... microscope to open new horizons in biological imaging. ... excitation, the decay of a fluorescence emission can ... measured. Subtle changes in the local environment ...
Biology Products: